Two-Step Blood & Scan Strategy Detects Early Alzheimer’s
- This study,published in JAMA Neurology,investigated the potential of a blood test measuring phosphorylated tau 217 (p-tau217) to identify amyloid beta (Aβ) status in people without cognitive impairment.
- * Alzheimer's disease is a major global health concern, and current diagnosis relies on expensive and invasive methods (brain scans or spinal taps).
- * Researchers analyzed data from 12 cohorts across multiple countries (US, Europe, Australia, Canada) involving 2916 cognitively unimpaired adults.
Summary of the JAMA Neurology Study on Plasma p-tau217 for Alzheimer’s Disease Detection
This study,published in JAMA Neurology,investigated the potential of a blood test measuring phosphorylated tau 217 (p-tau217) to identify amyloid beta (Aβ) status in people without cognitive impairment. here’s a breakdown of the key findings:
Background & Goal:
* Alzheimer’s disease is a major global health concern, and current diagnosis relies on expensive and invasive methods (brain scans or spinal taps).
* A blood-based biomarker could revolutionize early detection, allowing for intervention before symptoms appear.
* The study aimed to determine if p-tau217 in blood could accurately classify Aβ status,both as a standalone test and in combination with existing methods (PET scans or CSF analysis).
Study Design:
* Researchers analyzed data from 12 cohorts across multiple countries (US, Europe, Australia, Canada) involving 2916 cognitively unimpaired adults.
* Participants provided blood samples for p-tau217 measurement. Some also underwent amyloid PET scans or CSF analysis to determine their Aβ status.
* Statistical modeling was used to determine optimal cut-off points for the blood test and assess its accuracy.
Key Results:
* Standalone Blood Test: The p-tau217 blood test achieved 81% overall accuracy in identifying Aβ status.It had a positive predictive value (PPV) of 79%, meaning that 79% of those who tested positive on the blood test actually had Aβ positivity confirmed by other methods. However, it only identified about 46% of those with Aβ positivity (lower sensitivity).
* Two-Step Workflow (blood Test + Confirmation): Combining the blood test with a confirmatory test (CSF or PET) considerably improved accuracy.
* CSF Confirmation: increased PPV to ~91%. CSF detected more true positives as it identifies changes earlier in the disease process.
* PET Confirmation: Increased PPV to ~99%. PET delivered higher PPV, reflecting its ability to detect more established pathology.
* Operational Impact: simulations showed that a two-step workflow could be more efficient for recruiting participants for clinical trials needing a specific number of Aβ-positive individuals.
In essence, the study suggests that a blood test for p-tau217 is a promising tool for identifying individuals at risk for Alzheimer’s disease, but a two-step approach – using the blood test to screen, followed by confirmation with CSF or PET – offers the best balance of accuracy and efficiency.